CASP12 is a caspase family member with putative roles in immune regulation and apoptosis. Based on functional annotation, CASP12 may act as a negative regulator of inflammatory responses by reducing cytokine release in response to bacterial lipopolysaccharide and inhibiting NF-κB activation following TNF stimulation 1. The protein localizes to the endoplasmic reticulum and cytoplasm and associates with the NLRP1 inflammasome complex, though it likely lacks active protease activity. In cervical cancer, CASP12 expression serves as an independent prognostic biomarker with clinical diagnostic value. Patients with low CASP12 expression demonstrated significantly worse outcomes, with serum CASP12 showing 86.5% diagnostic accuracy (AUC=0.865) for distinguishing cancer patients from controls 2. Low CASP12 expression correlated with increased lymph node metastasis, larger tumor size, advanced FIGO staging, and poorer 3-year survival rates 2. These findings suggest CASP12 functions as a tumor suppressor in cervical cancer, with reduced expression associated with aggressive disease characteristics. However, the mechanistic basis for CASP12's protective role in cancer remains unclear and requires further investigation.